Navigation Links
St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial
Date:11/9/2009

St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.

Under the clinical protocol, St. Jude will refer patients to receive proton therapy at the UF Proton Therapy Institute in Jacksonville, Fla. The purpose of the clinical study is to improve response rates and decrease treatment-related side effects.

Proton therapy is being studied as a way to reduce potential damage to healthy tissue that may result from conventional radiation therapy. This is especially important in treating children with brain and spinal tumors to potentially avoid interference with development, growth and cognitive functioning.

St. Jude has the world's largest protocol-based, pediatric brain tumor research and treatment program, which puts it in an excellent position to scientifically document the advantages realized with proton beam radiation therapy.

"Proton beam therapy is potentially of great importance to St. Jude and our patients," said Dr. Joseph H. Laver, St. Jude executive vice president and clinical director. "Although most proton facilities operating in the U.S. recognize pediatrics as a major area of focus, there is very little meaningful data using this modality in children. Working with UF Proton Therapy Institute, we are well-positioned to answer key questions regarding this therapy for children with cancer."

St. Jude patients accepted for the clinical study will be in Jacksonville for proton therapy treatment for six to eight weeks. It is expected that up to 15 patients will receive treatment during the first year of the study. While in Jacksonville, hospital care for St. Jude patients will be provided by Nemours Children's Clinic Jacksonville and Wolfson Children's Hospital. The Ronald McDonald House in Jacksonville will house St. Jude patients while they are receiving treatment in Florida.

"It is central to our mission to realize the full potential of protons in the treatment of children," said Dr. Nancy Mendenhall, medical director at UF Proton Therapy Institute. "In cooperation with St. Jude, we will have both clinical and research expertise to provide the best outcomes for patients and to create new knowledge that will guide the development of proton therapy for future patients."

St. Jude leads the field in the application of intensified modulated radiation therapy, known as IMRT. The technique is effective at avoiding damage to adjacent tissues; however, IMRT can still deliver significant radiation doses to underlying tissues resulting in unavoidable side effects for some children. Proton therapy can be focused more precisely and intensely on specific areas of cancerous activity. Protons can also be energized for a desired degree of tumor penetration, thus sparing underlying tissues from radiation exposure.

UF Proton Therapy Institute is one of only six proton therapy centers in the United States. Since opening in August 2006, UF Proton Therapy Institute has treated 100 pediatric patients.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
5. Proton-powered pooping
6. Wyeth Announces Launch of Own Generic Version of PROTONIX
7. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
8. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
9. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
10. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
11. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers ... and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 ... SHOT Show is the shooting, hunting and outdoor trade show and conference for ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, ... complimentary consultations and financing for orthodontics for a limited time. Complimentary for a ... about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date ... http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and advocate ... syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 - First major agreements signed with ... expected to grow by a CAGR of approximately 6-9% between ... company which operates globally across a number of sectors, announces that ... notable successes and is well-positioned for further expansion within the rapidly ... ...
(Date:1/17/2017)... , Jan. 17, 2017  Allergan Plc (NYSE: ... from Venus II, the second of two pivotal phase III ... in women with abnormal bleeding due to uterine fibroids.  A ... the second half of 2017. "We are pleased ... and safety profile of ulipristal acetate as shown in our ...
(Date:1/16/2017)... Research and Markets has announced the addition of the "Global ... ... drugs market to grow at a CAGR of 9.19% during the ... and the growth prospects of the global multiple myeloma drugs market ... revenue generated from the sales of branded and generic drugs used ...
Breaking Medicine Technology: